Search Results - "Byrne, J.L."

High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma by Bishton, M, Gilyead, M, Das Gupta, E, Williams, C, Russell, N.H, Byrne, J.L

“…Abstract We have used two strategies for treating myeloma patients aged 65–75 years. Those fit enough underwent Cyclophosphamide mobilisation and PBSCT using…”
Get full text

EP06.19: Prenatal diagnosis of Bardet‐Biedl Syndrome by Dalton, S., Griffith, A., Monson, M., Byrne, J.L., Woodward, P., Kennedy, A.

Get full text

OP 27.09: Prenatal diagnosis of sacrococcygeal teratoma ( SCT ) rupture by Kennedy, A., Woodward, P., Byrne, J.L.

Get full text

OP27.09: Prenatal diagnosis of sacrococcygeal teratoma (SCT) rupture by Kennedy, A., Woodward, P., Byrne, J.L.

Get full text

P 11.02: Prenatal diagnosis of metastatic neuroblastoma by Byrne, J.L., Woodward, P., Kennedy, A., Pysher, T.

Get full text

P11.02: Prenatal diagnosis of metastatic neuroblastoma by Byrne, J.L., Woodward, P., Kennedy, A., Pysher, T.

Get full text

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era by Fox, C P, Burns, D, Parker, A N, Peggs, K S, Harvey, C M, Natarajan, S, Marks, D I, Jackson, B, Chakupurakal, G, Dennis, M, Lim, Z, Cook, G, Carpenter, B, Pettitt, A R, Mathew, S, Connelly-Smith, L, Yin, J A L, Viskaduraki, M, Chakraverty, R, Orchard, K, Shaw, B E, Byrne, J L, Brookes, C, Craddock, C F, Chaganti, S

“…EBV-associated post-transplant lymphoproliferative disease (PTLD) following Alemtuzumab-based allo-SCT is a relatively uncommon and challenging clinical…”
Get full text

Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation by Bokhari, S W, Watson, L, Nagra, S, Cook, M, Byrne, J L, Craddock, C, Russell, N H

“…Reduced-intensity-conditioning (RIC) regimens have allowed older patients to have allogeneic hemopoietic progenitor cell transplantation (HCT). This…”
Get full text

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study by Lawless, Sarah, Sbianchi, Giulia, Morris, Curly, Iacobelli, Simona, Bosman, Paul, Blaise, Didier, Reményi, Péter, Byrne, J.L., Mayer, Jiri, Apperley, Jane, Lund, Johan, Kobbe, Guido, Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Basak, Grzegorz, Touzeau, Cyrille, Wilson, Keith M.O., González Muñiz, Soledad, Scheid, Christof, Browne, Paul, Anagnostopoulos, Achilles, Rambaldi, Alessandro, Jantunen, Esa, Kröger, Nicolaus, Schönland, Stefan, Yakoub-Agha, Ibrahim, Garderet, Laurent

“…The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world…”
Get full text

357: The use of adjunctive leukemia specific therapy to improve outcome in patients with chronic myeloid leukemia transplanted using a reduced intensity conditioning (RIC) regimen by Craddock, C.F, Griffiths, M.J, Arrazi, J.M, Siddique, S, Pallan, L, Lennard, A.L, Byrne, J.L, Olavarria, E

Get full text

PS1182 REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY by Milojkovic, D., Cross, N.C., Ali, S., Byrne, J.L., Campbell, G., Dignan, F.L., Fildes, L., McMullin, M.‐F., Neelakantan, P., Sivakumaran, M., Wandroo, F., Willis, F., Ryan, J., Clark, R.E., Mead, A.

“…Background: Response to tyrosine kinase inhibitor (TKI) treatment is a key predictor of outcome in chronic myeloid leukaemia (CML), as outlined in the European…”
Get full text

Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation by Shaw, B E, Lee, F, Krishnamurthy, S, Byrne, J L, Seedhouse, C, Mayor, N P, Maldonado-Torres, H, Saudemont, A, Marsh, S G E, Madrigal, J A, Russell, N H

“…Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however…”
Get full text

EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT by Fox, C P, Bishton, M J, O'Connor, S, Hughes, S, Byrne, J L, Russell, N

Get full text

A Comparison of Stem Cell Source in Recipients of T-Cell Depleted Myeloablative Transplants for Leukaemia: No Difference in Mortality Using BM or PBSC by Shaw, B.E., Russell, Nigel H., Pagliuca, A., Apperley, J., Cook, G., Mackinnon, S., Madrigal, J.A., Marks, D., Morgan, G.J., Peggs, K., Potter, M.N., Towlson, K., Byrne, J.L.

“…The use of GSCF-mobilised Peripheral Blood Stem Cells (PBSC) for unrelated donor (UD) transplantation has increased dramatically since 2000. The association of…”
Get full text

Allogeneic transplantation using peripheral blood stem cells by Russell, N.H, Byrne, J.L

“…Over the past 9 years there has been a remarkable increase in the use of peripheral blood stem cells (PBSC) for allogeneic transplantation, primarily for…”
Get full text

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH (± fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion by Lush, R.J., Haynes, A.P., Byrne, J.L., Cull, G.M., Carter, G.I., Pagliuca, A., Parker, J.E., Mufti, G., Mahendra, P., Craddock, C.F., Liu Yin, J.A., Garg, M., Prentice, H.G., Potter, M.N., Russell, N.H.

“…We report our updated experience of allogeneic transplantation in lymphoproliferative disorders using a reduced-intensity conditioning regimen combining BEAM…”
Get full text

Use of haemopoietic growth factors: commentary on the ASCO/ECOG guidelines by Byrne, J.L., Haynes, A.P., Russell, N.H.

“…In the past two to three years, a number of clinical guidelines have been issued that have attempted to recommend specific indications for the use of…”
Get full text

Local Dietetic Associations can Facilitate Collaborative Clinical Practice Research by TU, NATALIES, GUZIK, CATRINE J, RICKETTS-BYRNE, JANINE L, WEDDLE, DIAN O

“…A model that a group of dietitians followed to organize and perform a multisite study is described. The American Dietetic Association has called on dietitians…”
Get full text

Listeria monocytogenes in lemming by PLUMMER, P J G, BYRNE, J L

Get full text